Karyopharm Therapeutics (NASDAQ: KPTI)

Ripe Buyout Candidate

Do your own research. This page does not provide investment advice.

Upward Trend

Most of the shares are in institutional hands who are not trading it. The few shares left are in our hands. So most of the volume is day trading and games market makers and hedge funds play. The bulk of the volume will come when buyers and shorts pull the trigger to buy/cover shares.

The trend seems to be for that to happen they have to bid up the price to get sellers to agree to sell. Institutions know the potential of the company and doubt would sell any time soon. So we should see bidding up the price as prospects continue to improve. Given the stock is undervalued, such move could come even without material news.

Piper Sandler Conference

Piper is a heavy weight in biotech M&A - so talks could be happening.


Deck: https://investors.karyopharm.com/download/Piper+HC+Conference+KPTI+Presentation_+Final_+November+29+2022.pdf

Excellent presentation. CEO's emphasis on seniority of the team is important -- they're doing some very scientifically intense heavy lifting and they have the right team to do ti.

MDS interim data not out yet which is a positive - the longer it takes the better.

Announcement in ASH (December 2022) about Myelofibrosis should be significant.

Lot of new data expected in 2023 including phase 2/3. As saying goes, most money is made on phase 2 data.

150 million revenue, drug approved in over 40 countries, rich pipeline.

Latest Presentation


Positive outlook for biotech 2023 Outlook

Bio: It’s Time for Biotech Firms to Outshine S&P500 Healthcare Players www.businesskorea.co.kr/news/articleView.html?idxno=104629

2948 Selinexor in Combination with R-GDP for Patients with Relapsed/Refractory B-Cell Lymphoma: Final Results of 18 Patients Treated at RP2D of Selinexor in the Selinda Phase Ib Lysa Study

Program: Oral and Poster Abstracts

Session: 626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster II

Hematology Disease Topics & Pathways:

Combination therapy, Therapies

Sunday, December 11, 2022, 6:00 PM-8:00 PM


GSK Could Eye Karyopharm

GSK plc (LSE/NYSE: GSK) has initiated the process for withdrawal of the US marketing authorisation for Blenrep (belantamab mafodotin-blmf) following the request of the US Food and Drug Administration (FDA).

Belantamab Mafodotin to Be Withdrawn From US Market for Relapsed/Refractory Myeloma


Good Companies Are Bought Not Sold

To all the people who write "sell the company", remember, good companies are bought not sold. Mike Kauffman the last disaster CEO told me on a zoom call that they had overtures in the past but told the prospective buyer "not yet". And he said it's like sending your kid to university - and they want to send their kid to Ivy League. So that would be like Pfizer or Roche or something -- so we'll see.

Of course this idea of beiing bought not sold does not mean a company has to sit still and do nothing about promoting itself. Sharon Shacham the genius inventor of Selinexor told me on a Zoom call buyout discussions are like dating.

I told her, using another analogy, that the idea of standing there waiting to be asked to dance is outdated -- the company has to promote itself as well. The best example is ARIAD CEO Paris Panayiotopoulos who shrewdly got a great valuation for Ariad.


3969 Novel Combination of Clinical Menin Inhibitor Ziftomenib and the Nuclear Export Inhibitor Selinexor Synergistically Inhibit MLL-r AML

  • Program: Oral and Poster Abstracts

  • Session: 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster III

  • Hematology Disease Topics & Pathways:

  • Research, Acute Myeloid Malignancies, Translational Research, Combination therapy, Diseases, Therapies, Myeloid Malignancies

  • Monday, December 12, 2022, 6:00 PM-8:00 PM


Very Significant Buyout in KPTI Space; Barclays Issues Optimistic View on Karyopharm

Merck just acquired Imago Biosciences for $1.35 billion to boost Merck's hematology pipeline. Barclays issued positive view on Karyopharm, noting he transaction will have a positive read-through to biotechs focused on hematological malignancies such as Karyopharm (KPTI).

Lisa A. DiPaolo, Chief Human Resource Officer of Karyopharm Named as 10 Most Influential HR Exec




With KPTI current sales. Plus what they have going on in trials and pipeline. A 2 billion dollar market cap is very modest. That would be $25.00 per share

Upgrades, Nov 2022

RBC Capital analyst Brian Abrahams upgrades Karyopharm Therapeutics from Sector Perform to Outperform and raises the price target from $7 to $10.

SVB Leerink analyst Jonathan Chang maintains Karyopharm Therapeutics with a Market Perform and raises the price target from $5 to $6.


RBC Capital Markets has upgraded Karyopharm Therapeutics to outperform from market perform saying the company's opportunities are discounted in the stock price. The firm also upped its price target to $10 from $7. Analyst Brian Abrahams highlighted cancer treatment Xpovio (selinexor), which he said could achieve $700M in annual sales based on its activity across multiple tumor types. He added that Xpovio could see growth with potential approval in myelofibrosis and endometrial cancer. He sees ~$300M in peak sales for the former indication, and the latter adding ~$140M in revenue.

Ex-CEO Michael Kauffman

Ex-disaster CEO Michael Kauffman (great doctor/scientist) used to sell regularly. He told me his financial consultants told him it's crazy to be so concentrated in one stock. The last 13G/A he filed was in Feb 2022. He hasn't sold since then. That's a good sign. He owns over 4 million shares. Also his wife, Sharon is a big holder.

KPTI back to $14

Not long ago the stock went from $10 to $14 because the company cancelled a meeting. Sounds crazy, and it is, when the short interest is so high, and the stock is so manipulated to such ridiculous valuation. I expect we'll see that happen again; perhaps not a cancelled meeting but the real nightmare of shorts: buyout discussions.

KPTI, the world leader in SINE technology at JEFF Biotech Conference in London

The whole gang is in London. I hope they're also meeting with Roche and other prospective acquirers in UK and Switzerland.


Our rock star, Sohanya, say 60 mg dose is used off label. Doctors are getting confident with the dose reduction which improves progression free survival.

KPTI bashing by prospective buyers, to get in for cheap!

I'm very pleased to see stupid bashing by KPTI prospective buyers (shorts who are getting margin calls to cover or otherwise see the writing on the wall and make the right decision to cover; or others who want to buy the shares). I sense a desperation in their bashing messages.

Usually bashers attack a company's science, market, prospects, etc. which requires solid arguments that can't get debunked. Since such arguments are impossible to make against Karyopharm, the bashers have resorted to stupid lies, like posting "CEO selling tons of shares". No he's not. That's a flat out lie. The CEO sold a few shares to pay options tax. That's very customary and happens in every company, and he is the beneficiary owner of hundreds of thousands of shares. Try again!

Institutional quarterly filings are coming in. Ally Bridge Group took on a new 1.5 million share position in KPTI worth $8.5 million!

More should be filed by end of day tomorrow.

Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma (XPORT-EC)


Karyopharm holds company call after results of competitor drug failing (good news for Karyopharm)

  • GSK's CAR-T rival Blenrep fails multiple myeloma trial, endangering its accelerated approval. GSK’s dream just turned into a nightmare.

  • The company’s BCMA-targeted Blenrep has failed a phase 3 trial in relapsed or refractory multiple myeloma. The GSK antibody-drug conjugate didn’t outdo Bristol Myers Squibb’s Pomalyst and low-dose dexamethasone at slowing disease progression or death, the company said Monday.

  • The DREAMM-3 trial flop is a blow to GSK’s oncology ambitions; the British pharma has projected Blenrep could reach more than 3 billion pounds sterling in peak sales. And it puts Blenrep’s accelerated approval in multiple myeloma in danger.



Preliminary Results from Two Clinical Studies of Selinexor to be Presented at 2022 ASH Annual Meeting

“The data to be presented at ASH 2022 highlights the broad clinical potential and manageable side effect profile of selinexor in patients with well-defined T-cell lymphomas and R/R MM,” said Dr. Jay Mei, Antengene’s Founder, Chairman and CEO. “It is our great pleasure to share these updates with the hematology/oncology community at ASH 2022.”


GETTING CLOSER TO BUYOUT? Piper Sandler connection is a hint? Barclay had predicted buyout price of $60 / share for KPTI.

I don't recall Karyopharm ever attending a Piper Sandler conference before. Mind you merger & aquisitions is a specialty of PS. At this stage in Karyopharm's history, getting aquired is a natural. Price tage? Barclay had a $60 aquisition price targer for KPTI and put KPTI on top of their buyout candidate list last year. Things have only gotten better.

NEW CONFERENCES. NOTE: PIPER SANDLER is a specialist in capital markets and M&A advisory services.

Live webcast: http://investors.karyopharm.com/events-presentations

Jefferies 2022 London Healthcare Conference

Piper Sandler 34th Annual Healthcare Conference

Buyout prospects

7 Nov 2022 -- Buyout prospects just increased with the last earnings report. Big Pharma could make a move any time. I have a lot of faith in Richard Paulson. But don't know his negotiation skills. If he plays his cards right he can get competitive bids and we're talking mega buyout price.

Excellent 2022 Q3 Progress

Great earnings report; great sales numbers; great scientific progress; Richard Paulson sounded stronger and more confident than ever. I'm confident my investment is in right hands. I sent them a congrats note. It's just a matter of time before the company is bought by a big pharma for a luscious premium.

KPTI had a good quarter - revenues increasing nicely - revenue guidance reiterated - and company has made a lot of important scientific progress. I continue to be very bullish on KPTI and believe the company will be bought by a big pharma early to mid 2023 at much higher value than today's stock price.

I'm planning to hold my shares till the company gets bought out. That's my exit strategy.


§ Brokerage Firm: RBC Capital Mkts | Action: Upgrade | Ratings Change: Sector Perform » Outperform | Price Tgt: $7 » $10

§ $KPTI SVB Leerink analyst Jonathan Chang maintains Karyopharm Therapeutics with a Market Perform and raises the price target

Karyopharm Announces New Selinexor Data in Myelofibrosis and Multiple Myeloma to be Presented at ASH 2022

Encouraging Data Observed in Phase 1 Study of Selinexor in Combination with Ruxolitinib in Treatment-Naïve Myelofibrosis, Including Activity Across Three Key Efficacy Endpoints of Spleen Volume Reduction, Symptom Improvement, and Hemoglobin Stabilization, with a Generally Manageable Tolerability Profile and No Dose Limiting Toxicities–

– New Data on Triple Class Refractory Multiple Myeloma Patients Continue to Highlight the Efficacy and Tolerability of Selinexor in the Treatment of Multiple Myeloma –


Selinexor demonstrates anti-tumor efficacy in paired patient-derived xenograft models and hydrogel-embedded histoculture drug sensitivity test of penile cancer


The PDX model of penile cancer was a powerful tool for penile cancer research and new drug development. It showed that Selinexor can effectively inhibit penile cancer in vitro and in vivo. In addition, XPO1 may affect P53, P21, and Cyclin D1 expression to regulate the growth and apoptosis of penile carcinoma.


A novel anti-cancer therapy with nuclear export inhibitor Selinexor in combination with oncolytic myxoma virus

These results for the first time indicate that Selinexor in combination with oncolytic MYXV can be used as potential new anti-cancer therapy.




In pts with treatment-naïve MF, QW SEL in combination with RUX is well tolerated with a manageable side effect profile. Based on current data there have been no observed dose limiting toxicities in cohort 1 of QW oral SEL 40 and 60 mg with RUX.


Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of Myelofibrosis


A Study to Evaluate Safety and Efficacy of Selinexor Versus Treatment of Physician's Choice in Participants With Previously Treated Myelofibrosis


Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications


A Study to Evaluate Safety and Efficacy of Selinexor in Combination With Ruxolitinib in Participants With Myelofibrosis


Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors (ESSENTIAL)

This is a phase II, open label, prospective, single-arm study evaluating the efficacy and safety of selinexor in patients with PMF or secondary MF (PPV-MF or PET-MF) who are refractory or intolerant to ruxolitinib and/or any other experimental JAK1/2 inhibitors.


Antengene Announces XPOVIO® Regulatory Approval in Taiwan

Antengene Announces XPOVIO® Regulatory Approval in Taiwan for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Diffuse Large B-Cell Lymphoma. TFDA has approved XPOVIO® (selinexor) for three indications.


Ripe Buyout Target

Here's a stock I'm very excited about: KPTI. It has over 90% institutional interest. MS has been flip flopping on it and the short interest is very high, but shorts on the wrong side of science. It makes drugs for incurable diseases. The valuation is ridiculously low at the moment and manipulated by the short interest. It's a ripe buyout target. Barclays had a $60 buyout price target for KPTI. Since then there's only been positive developments. Biotechs have hiccups along the way, which are sometimes influences and orchestrated by short interest influence, but at the end of the day, Karyopharm will come out shining and will probably get bought out at a couple of billion dollars or more (current valuation: 390 million).

Selinexor: Rationale for Use in R/R MM Patients


Endometrial Cancer Edition with Dr Mansoor Raza Mirza


Conversations Around Selinexor: Best Nursing Practices in Multiple Myeloma


Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)

These data suggest that the combination of venetoclax and selinexor is effective and t(11;14) may serve as a therapeutic marker for response and target for future clinical trials.


Karyopharm has an amazingly competent CMO: Dr. Reshma Rangwala, MD, PhD.


I just listened to her talk at Morgan Stanley Healthcare Conference and was very impressed. She's totally on top of things, and had this rock star level of excellence about her -- despite an analyst whose attitude was questionable (not surprising given the huge short interest which is on the wrong side of science). Karyopharm is going after several incurable diseases and short interest and a team of scums, Vinay Prasad, Aaron Goodman, Al-Ola A Abdallah, Manni Mohyuddin, Bijoy Telivala, some of whom have questionable affiliations and apparently even link to hedge funds, have tried to derail and badmouth our life saving drug. They're being proven wrong. Read more about it here: https://www.rezamusic.com/writings/law-ethics/Selinexor-bashers-and-link-to-hedge-funds

Site Update

Management team page is finally sorted out (after several messages I sent them that it made no sense: it wasn't alphabetical, and it wasn't according to importance or position. It was just random which looked unprofessional. Now it's alphabetical. Also, management team is optimized -- a smaller, leaner team. Still a couple of B players among them but I trust in Richard's decisions. https://www.karyopharm.com/about/management-team/

Dr. Ali on Key Findings From the Phase 1 Study of Selinexor Plus Ruxolitinib in Myelofibrosis


"Data presented at the 2022 ASCO Annual Meeting demonstrated that the combination of selinexor and ruxolitinib was safe and tolerable in all patients"

Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients


"Selinexor is Incredibly Helpful... It Performs Very Well"


In this video, Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the role of selinexor in the treatment of multiple myeloma, emphasizing its value in patients with del(17p)-positive relapsed/refractory (R/R) disease. Dr Richardson also highlights some of the challenges associated with the use of selinexor, and clinical trials evaluating the safety and efficacy of this agent. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

Big Data Coming Up

It's well known that in pre-approval phases, phase 2 data is where the big money can be made. KPTI has a phase 2 data coming out by end of this year. The current valuation is ridiculously low however you look at it. The upcoming phase 2 data is worth the entire current market cap, let alone KPTI's multiple approvals in multiple markets that are currently revenue generating.

Real-World Use of Selinexor, Daratumumab and Dexamethasone in Chinese Patients With Multiple Myeloma at First Relapse


Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma


Gasparetto Discusses Sequencing Selinexor in Relapsed/Refractory Multiple Myeloma

September 22, 2022

Targeted Oncology Staff

Case-Based Roundtable Meetings Spotlight, Case-Based Roundtable Meetings Spotlight: September 2022,




Notes From Presentation At Morgan Stanley

12 Sep 2022


Manirini To Buy Karyopharm?

"ELZONRIS is their only FDA approved drug. They bought it from the developer. Both Stemline and Menarini are growth through licensing & buying. The breast cancer drug currently in front of FDA is licensed from Radius Health. Looks like Menarini is using Stemline to launch this breast cancer drug + Menarini is focusing on having their own oncology franchise and plans to break into the US. On the Menarini website, it also mentioned MDS and MF as their focuses..."

Some of the other possibilities are Sanofi and Roche.


25 July 2022

When Aaron Goodman bashes KPTI you know it's time to buy. There's evidence of link between him and an agency hedge funds use to retain "consultant" doctors. Is Goodman a paid shill? We can't prove it but he looks like one.

Fact is #selinexor has an excellent safety profile and is well managed by a huge number of doctors and the drug saves lives and works wonders. Just a bunch of fringe bozos on Twitter get a kick out of trash talking a life saving drug. And some have been linked to hedge funds.


There's evidence that links Aaron Goodman to an agency that hedge funds use to hire "consultant" doctors.

It's well known the shorts hire doctors to trash talk a drug they're short on. I was in elevator and heard conversation of one hedge fund manager with a puppet medical doctor. I also had exchanges with Shkreli (convicted criminal hedge fund manager) who paid doctors to trash talk stocks. If they hired Goodman or not we don't know but it happens.

Their goal is to weaken sales and dissuade doctors and ultimately debilitate the company. They especially do this to companies they know have no teeth or a weak legal department.

Selinexor inhibits growth of patient derived chordomas in vivo as a single agent and in combination with abemaciclib through diverse mechanisms


Good News: Court dismisses ambulance chasers' lawsuit against Karyopharm.


On August 5, WilmerHale scored a significant win for client Karyopharm Therapeutics when the First Circuit unanimously affirmed a decision from the District of Massachusetts dismissing a securities class action suit. The WilmerHale team representing Karyopharm includes Peter Spaeth, Allyson Slater, Jocelyn Keider and Mike Bongiorno, who argued the case on appeal.

I hope plaintiff was ordered to cover Karyopharm's legal costs.



Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)


Big Pharm Interest in Karyopharm

KPTI co-founder, Sharon Shacham told me last year they had interest from big pharma but told them "not yet". And their kid has grown and they want it to go to Ivy League which in my view he meant a big top notch pharma like PFE Pfizer, MRK Merck. His wife (co-founder) told me talking with pharma prospective buyers "is like dating" and that she was not good at it :-) Let's hope Richard is :-)

Karyopharm Granted Regulatory Designations for Eltanexor for the Treatment of Myelodysplastic Syndromes


“Wood and team found that a combination of Selinexor and an AKT inhibitor work much better than chemotherapy, which is the current standard of care for otherwise healthy patients.”


P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia


Selinexor Maintenance Improves PFS in Advanced or Recurrent Endometrial Cancer, Particularly p53 Wild-Type Subset


Selinexor in Patients from Argentina with Multiple Myeloma Treated with Multiple Prior Therapies: A Case Series


A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations

The purpose of this study is to evaluate the efficacy and safety of selinexor alone or with pembrolizumab in participants with advanced or metastatic colorectal cancer (CRC). Approximately 78 participants with advanced or metastatic CRC will be enrolled, and randomized (1:1:1) into three arms A (selinexor only), B (selinexor and pembrolizumab), and C (standard of care [Combination of trifluridine and tipiracil]). Randomization will be based on stratification factors: Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 versus 2. The end of treatment (EoT) visit will occur less than or equal to (<=30) days post-treatment discontinuation. A survival follow-up visit will be performed every 3 months from EoT and will continue for 12 months.


Combination Venetoclax and Selinexor Effective in Relapsed Refractory Multiple Myeloma with Translocation t(11;14)


26 Jul 22 - A combination comprised of selinexor (Xpovio) and ruxolitinib (Jakafi) induced rapid spleen responses at week 12 and showcased a manageable toxicity profile in patients with treatment-naïve myelofibrosis.


The combination of selinexor and ruxolitinib has been well tolerated and with a manageable [adverse] effect [AE] profile,” lead study author, Haris Ali, MD, an associate professor in the Department of Hematology and Hematopoietic Cell Transplantation, of the Division of Leukemia, at City of Hope Comprehensive Cancer Center, and colleagues, wrote in a poster on the data. “No dose-limiting toxicities [DLTs] were observed in patients with treatment-naïve myelofibrosis who received once weekly oral selinexor at 40 mg or 60 mg in combination with standard-dose ruxolitinib.”


#selinexor saves lives. Excellent safety profile. Thanks Dr. Haris Ali @harisali_md. Well done.

Don't let the sucker Aaron Goodman @AaronGoodman33 and hedge funds who are short #KPTI find out. #oncology #Xpovio #ruxolitinib #Jakafi #myelofibrosis


21 July 2022 - Big News is out. This approval will boost revenues, makes Karyopharm even a more attractive buyout candidate, and changes valuation models. Analysts upgrades should come soon. Current valuation is ridiculously low. Last year an analyst assigned a $60 buyout price target. Things have only gotten better since then. A big victim of stock price manipulation, KPTI is set to rebound strongly in the months ahead as revenues increase and buyout prospects get better and better. I am critical of the CFO and Legal Counsel and think those departments can significantly improve with better leadership, but am very optimistic overall. Do your own research. Congrats to Richard Paulson and Karyopharm team for this important approval which seemed like Mission Impossible a few months ago.

Karyopharm and Menarini Group Receive Full Marketing Authorisation from the European Commission for NEXPOVIO® (selinexor) for the Treatment of Patients with Multiple Myeloma After at Least One Prior Therapy

– Based on Results from Phase 3 BOSTON Study, Marketing Authorisation Expands Multiple Myeloma Indication –

– Approval Follows Positive Opinion by European Committee for Medicinal Products for Human Use (CHMP) in May 2022 –

European approval seems to be shoe in

7.19.2022 - DL/2022/5395 - C(2022) 5253 - COMMISSION IMPLEMENTING DECISION granting marketing authorisation under Regulation (EC) No 726/2004 of the European Parliament and of the Council for "NEXPOVIO - selinexor", a medicinal product for human use and repealing Decision C(2021)2299(final). Waiting for C(2022) 5253 Decision details to be published. But "granting" sounds positive., supposing it is replacing Decision C(2021)2299.

Karyopharm Granted Regulatory Designations for Eltanexor for the Treatment of Myelodysplastic Syndromes

– FDA Fast Track Designation and European Commission Orphan Medicinal Product Designation Underscore the Significant Need for New Treatment Options for MDS

Locking Leukemia’s Cellular Escape Hatch


“Wood and team found that a combination of Selinexor and an AKT inhibitor work much better than chemotherapy, which is the current standard of care for otherwise healthy patients.”

P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia


CEO Richard Paulson beneficially owns about 660,000 shares. At a $30 buyout price he'll cash in $20 million. At $50 he'll cash in $33 million. But they urgently need a new CFO, in my view.


Very bullish sign when bashers are resorting to outright lies to try to disparage the company. If the company. One such lowlife with a new ID and no prior posts wrote today that Sohanya sold all her shares. She just sold a few bucks worth out of her around 90,000 shares to pay taxes on options which is very normal. I wish the company's legal arm had some balls to go after these bashers but Michael Kauffman hired average, passive people who were below him. Ace CEOs hire people better than themselves. C minus CEOs hire D people.

So let's see Richard shake up the company into a lean and mean place instead of being a punching bag for Wall Street crooks.


Yesterday, 7 July 2022, I had a 40 minute call with Karyopharm's IR director and their legal council.

I asked them things, I gave them tips / ideas which they said they appreciated.

I am not fond of their legal council.

Unfortunately the IR VP is reporting into the CFO.

The CFO and the legal council were hired by Mike Kauffman - and they're both called Mike. Dr.Kauffman was lousy CEO whom some people think I was instrumental in helping oust him. D-CEOs hire people below them. Ace CEOs hire people who are better than them.

Both Mikes are weak links in my view, and still embody the weak management of Kauffman and the culture he set in.

I questioned them on the Delphi transaction. Upon scrutiny and analysis on my part and their statements, bottom line is they claim they didn't tell the Board on June 7 or June 8 when they got the notice from Biogen. How inept is that?! And Delphi's transaction the next day was therefore just a coincidence! Right! Mano got defensive and asked if I'm thinking he's a lying that Delphi didn't know. I don't know the facts but never assumed he was lying. I remained puzzled and didn't conclude "oh he must be lying". Something doesn't add up. SEC may investigate Delphi. Till will tell.

And then it took KPTI 8 days to release a PR. Mano said we're working on improving out timing! What?! They haven't even gotten timing of PRs handled? Why did it take 8 days?

All this seems to fall in Mike Mano's department -- he was somewhat defensive which further confirms that. It's sloppy at best, IMO.

In my view, this screams of mismanagement. Great science but the IR/Legal side of the company still appears weak, and guess who's in charge of them: the two Mikes.

Elhan, the IR director is a nice, decent lady. Mano is also a nice guy and three of us had a good contact. I even played her a Turkish song on the guitar at the end of the call (we talked about guitar earlier), which they liked. She even understood the words, though I sang them with Azeri accent.

She kept answering me with "investor calls" -- I gave her tips about a lot that can happen outside investor calls.

Argot is in the picture with a reduced role (good). Gave them some tips I got from other CFOs about need to actively manage these thin-spread external IR firms.

We established a reliable channel of communication (me emailing Elhan). Although I could choose to write to Richard directly esp. given Mike Mason is Elhan's boss and I don't believe he's been investor friendly. And I'm not happy with the cost structure and I have no confidence in him as CFO, esp. regarding him calling shorts on ATM (I relayed a message to him that use of ATM at these prices would be utterly irresponsible). But I'm not selling my shares because of that. I'm holding till buyout.

Regarding countering disparagement by short cartel, their hired doctors (consultants) - I don't see it in Mano's profile any "teeth".

At the end Mano was like this is a talk between me, Mike Mano and you (trying to persuade me not to relay anything to public). I reminded them these are formal discussions between the company and the public and there's no need for them to be confidential - since nothing private was told to me. Hello!

Also told Elhan about history / founder's syndrome - she hadn't heard about it. And that she needs to be disruptive to inherited status quo. But given she reports to Mason I'm not holding my breath.

Mano wanted more info on my statement that Kauffman was a terrible CEO in my view. I elaborated some reasons.

It felt I had to reiterate some basics for them: that public company's management is hired by shareholders to build shareholder value, and detailed the factors that go into it, e.g. confidence on demand channel - marketing of the security - etc. etc.

And other topics, like BP manipulating share price; notes on buyout prospects and what the founders told me on the two zoom calls I had with them.

It was more of a learning experience for them than for me. They got to tap into the intensity of the challenge they're faced and that us shareholders hold them accountable.

I will keep my shares till buyout.


Company is still bogged down by repercussions of Michael Kauffman's mismanagement, in particular a couple of people he hired, Mike Mason as CFO and Mike Mano as Legal Counsel. In my view, based on a number of observations. Shorts have upped their stake probably knowing the company's weakness in these areas (CFO and Legal). Great science, great medicine, in hands of people who have proven to be incapable of building shareholder value. But I'm still not selling my shares. If you want to contact the management contact me for their email addresses off contact page of https://www.rezamusic.com/various/kpti


6/7 $KPTI gets news from partner. No big deal, not part of valuation – but shorts would abuse it to pound the stock.

6/8 Delphi/Deepa sells a lot of shares. Saves $1.3m in opp loss.

6/10 Delphi files S4.

6/15 Finally, KPTI makes public disclosure.

Stock tanked from June 8 onwards and Delphi got a great price. Deepika as Director should have been informed on 6/7.

KPTI's lawyer, Mano, told me the Board was not informed of the news prior to D’s sale. Why not?! He forgot to tell them?!

Was 6/8 sale totally random? True D was long term venture cap but still, timing is very fishy. Did D find out in another way than formally by Mano/co? Possibly.

Mike Mano was hired by Mike Kauffman who was a terrible CEO. Mano told me they’re trying to improve their PR timing. Seriously? After all this time and money they still can't get that right? Insider sale + legal dept screwup? I won’t be surprised SEC investigates Delphi’s sale. I’m not selling my shares till buyout, regardless.

M&A is down, but Big Pharma likely to line up 'multiple shots on goal' in 2nd half, PwC says


Price Jolt Two Week Cycle

An experienced investor said when there are jolts it takes 2 weeks for it to settle. I agree. KPTI broke down after a non-event deal cancellation on something that was not even in the valuation picture, coupled by a director (hedge fund) selling a small fraction of her holding which some speculated may have been related to crypto crash. Neither of these were justification for the price breakdown, so I'm on the side of those who think some market makers are manipulating KPTI. In that scenario, the stock falling under $5 triggered margin calls at some brokers. I know as a fact some brokers don't even let self-directed accounts to buy stocks under $5 and some major brokers don't provide margin buying power for stocks under $5. So these 3 factors created a jolt. I don't think there were any real, big sellers. But games including naked shorting by MMs. But these have a short cycle of about 2 weeks for dust to settle and start of buys that historically have caused sudden rebound.

PS -- Add to the manipulation mix end of quarter window dressing by hedge fund shorts to maximize their performance and fees.

New Positive Finding

Mount Sinai looked at the genomics of your super responders, found that cancers that don't respond to chemotherapy +- radiation respond to Selinexor with deep and durable responses.


Straight out of small biotech playbook. Next step: Buyout.

$ARNA was taken out of retail hand and sold to Pfizer ($PFE). I’ve seen many examples of biotechs where retail holds majority shares and supports the company for years, then professional investors get involved and play their tricks and get retail to sell and they get majority of the shares then the company gets sold for a big premium. ARNA was $15 before reverse split after their lousy Founder/CEO was fired by the board which many believe was due to our efforts (and me specifically as active investor group). That $15 share was bought by Pfizer for $100 a few years later. $KPTI (Karyopharm)’s founder/CEO was fired last year (again many think our/my efforts was the catalyst) – and institutional interest has been rising. Next in the play book is a buyout for a rich premium, in my opinion. So I just hold my shares. Heavy manipulation is expected as another 10% of the company is in retail hands and needs to shift to institutions. So games are played abundantly. I just hold and smile and wait it out. Experts believe 2nd half of 2022 will see many bio-pharma M&A's. KPTI was on top of Barclay's M&A list for $60 a share last year. Nothing has changed except manipulation to shift wealth from retail to institutional hands. Retails who hang in there win. In my opinion; not an investment advice.

Antengene Announces Clinical Trial Collaboration with BeiGene to Evaluate Selinexor in Combination with Tislelizumab in T and NK-Cell Lymphoma


Excellent New Presentation at Jefferies / Sales on track


Management reiterated guidance for the year. Sales are on track, despite efforts of the hedge fund doctor puppets to derail sales.

Selinexor is Approved in 38 Countries

38 countries! More approvals coming.

Canada Approved Selinexor

FORUS Therapeutics Inc ("FORUS") Announces XPOVIO® (selinexor) Is Authorized for Sale by Health Canada

Selinexor and an AKT inhibitor work much better than chemotherapy

Locking Leukemia’s Cellular Escape Hatch

“Wood and team found that a combination of Selinexor and an AKT inhibitor work much better than chemotherapy, which is the current standard of care for otherwise healthy patients.” P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia


Interview With CEO

Q&A with Karyopharm Therapeutics



§ The stock has been on a roller coaster along with XBI.

§ Institutional interest is almost 90% again (89.19%). I really like this metric because it shows level of conviction of institutions who generally do a lot of due diligence before buying a stock.

§ KPT Is more sensitive to XBI these days because also XBI increased its holding.

§ The company's founders should be rolling off the management page on the website any day. That's a good thing.

§ ASCO meeting starts this Friday. Karyopharm will be presenting new Selinexor data.

§ Short interest is at 14.5 million shares. They rise in short interest corresponds with latest price drop but it is artificial supply given institutional interest has been going up, so that could increase chance of short squeeze.

§ The company's presenting at Jefferies' in NY on June 9.

§ The company is presenting at EHA in Austria on June 9-12.

§ Phase 3 trials are cool. They put the company one step closer to more revenue. A P3 Study Evaluating an All Oral Regimen of Selinexor in Combination with Pomalidomide and Low-dose Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma has started and it's paid for by a MM coalition. Can't beat that.

§ EU approval will likely be granted this month. Menarini Group is ready to hit the ground running.

§ KPTI's investment thesis right now, in my book, is valuation, valuation, valuation. Any way I look at it the company ought to be three times current value currently. It'll get there, in my opinion.

§ Buyout written all over this stock. The ex-founder told me it's effectively a matter of when not if. I can wait. Amgen and Pfizer are on top of my list.

§ Revamped my KPTI info page: https://www.rezamusic.com/various/kpti

Karyopharm to Present New Selinexor Data at the 2022 American Society of Clinical Oncology Annual Meeting

– Encouraging Initial Data Observed in Phase 1/2 Study of Selinexor in Combination with Ruxolitinib in Treatment-Naïve Myelofibrosis, Including Favorable Tolerability with No Dose Limiting Toxicities and 75% of Evaluable Patients Demonstrating ≥35% Spleen Volume Reduction (SVR 35) at Week 12 –

– FDA Grants Orphan Drug Designation for Selinexor for the Treatment of Myelofibrosis –

– Exploratory Subgroup Analyses from SIENDO Trial in Patients with Endometrial Cancer Treated with Selinexor as Maintenance Therapy Identified p53 Wild-type as a Potentially Important Predictor of Efficacy, with 10-month PFS Improvement over Placebo; No Benefit Was Seen in Patients with p53 Mutant Tumors –


GREAT NEWS: Another Phase 3 trial and good phase 2 data and paid by an expert group!!

The European Myeloma Network and Karyopharm Announce Dosing of First Patient in Collaborative EMN29/XPORT-MM-031 Study

- Phase 3 Study Evaluating an All Oral Regimen of Selinexor in Combination with Pomalidomide and Low-dose Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma -



Full EMA approval could come before end of June. Kimmtrak was approved by EMA 38 days after CHMP approval. On 25 Feb Kimmtrak was recommended by CHMP. It was approved on April 4. 60 days is max. 38 days for Karyopharm means 26 June.


Karyopharm and Menarini Group Receive Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma

European Commission Decision Anticipated within Approximately 60 Days


Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the European Hematology Association 2022 Hybrid Congress

Excellent presentation at RBC CAPITAL

https://www.veracast.com/webcasts/rbc/healthcare2022/j34239.cfm -- Management came across as extremely confident.

Antengene Announces Commercial Availability of XPOVIO® (Selinexor), for the Treatment of Relapsed/Refractory Multiple Myeloma, Prescribed for the First Time Across Mainland China


Antengene Announces XPOVIO® (selinexor) Data to be Presented at the Upcoming 2022 European Hematology Association Hybrid Congress



Karyopharm is pleased to give a warm welcome to Dr. Tomer Mark as our Senior Vice President of Medical Strategy! We are confident that his deep expertise within the hematology space will be invaluable as we continue to develop our core programs.




We got some top notch sales reps

e.g.Tanya Rivers Granados


Commodore Capital LP bought 4 million shares of KPTI. They're a young hotshot 5th Avenue biopharma investment firm.


'New paper is published "A Case Report of a 58-Year-Old Woman with a Diagnosis of High-Risk Myeloma Refractory to Multiple Line of Therapy and Treated with Selinexor, Bortezomib, and Dexamethasone Prior

to Allogeneic Stem Cell Transplantation."

In this paper, a case of a 58-year-old woman with high-risk MM who had received 8 prior treatment lines, and whose disease was refractory to ixazomib, bortezomib, and all immunomodulatory agents, is described. After everything stopped working, this patient was treated with selinexor, bortezomib, and dexamethasone (XVd). After 1 cycle of XVd, she achieved a partial response, and after 4 cycles, a very good partial response (VGPR). Therefore, stem cell transplantation was performed. She remained relapse-free for 13 months after initiating XVd. Good to see that Selinexor works well in patients which have no other options.'

KPTI Titles for Selinexor presentations at ASCO in June:

1. Phase Ib trial of selinexor (SEL) in combination with nivolumab (NIVO) alone or nivolumab plus ipilimumab (NIVO+IPI) in patients (pts) with advanced malignancies: The renal cell carcinoma (RCC) experience.

2. Phase 1b study of weekly split-dose selinexor in soft tissue sarcoma (STS).

3. Randomized phase III study of maintenance selinexor versus placebo in endometrial cancer (ENGOT-EN5/GOG-3055/SIENDO): Impact of subgroup analysis and molecular classification.

4. A phase 1, open-label, dose-escalation study of selinexor plus ruxolitinib in patients with treatment-naïve myelofibrosis.

5. Phase Ib study of selinexor and eribulin combination in advanced solid tumors and triple-negative breast cancer.


Karyopharm Announces Selinexor Data to be Presented at the 2022 American Society of Clinical Oncology Annual Meeting


Oral Presentation

Title: Randomized phase III study of maintenance selinexor versus placebo in endometrial cancer (ENGOT - EN5/GOG-3055/SIENDO): Impact of subgroup analysis and molecular classification

Presenter: Vicky Makker, Memorial Sloan Kettering Cancer Center

Abstract #: 5511

Date and time: Tuesday, June 7, 2022, 8:00 a.m. – 9:30 a.m. CDT

Session: Clinical Science Symposium/Molecular-Based Treatment for Endometrial Cancer

Poster Presentations

Title: A phase 1, open-label, dose-escalation study of selinexor plus ruxolitinib in patients with treatment-naïve myelofibrosis

Presenter: Haris Ali, City of Hope

Abstract #: 7060

Date and time: Saturday, June 4, 2022, 8:00 a.m. – 11:00 a.m. CDT

Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Title: Phase 1b study of weekly split-dose selinexor in soft tissue sarcoma (STS)

Presenter: Abdulazeez Salawu, University Health Network

Abstract #: 11563

Date and time: Sunday, June 5, 2022, 8:00 a.m. – 11:00 a.m. CDT

Session: Sarcoma

Title: Digital monitoring and assessments in patients with glioblastoma

Presenter: Yasaman Damestani, Karyopharm Therapeutics, Inc.

Abstract #: 2045

Date and time: Sunday, June 5, 2022, 8:00 a.m. – 11:00 a.m. CDT

Session: Central Nervous System Tumors

CEO Richard Paulson has a very impressive background. Solid business and sales and management experience unlike the last CEO who was just a good doctor/scientist and ran the company into the ground by mismanagement. Turnaround in progress.


Details of KPTI Presentations at American Association For Cancer Research April 8 to 13

· 4067 / 21 - Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14) https://www.abstractsonline.com/pp8/#!/10517/presentation/15278

· 5455 - Nuclear export inhibitor selinexor synergizes with proteasome inhibitor marizomib in preclinical models of glioblastoma https://www.abstractsonline.com/pp8/#!/10517/presentation/17686

· 1122 / 12 - Selinexor synergizes with IL-12 to inhibit tumor growth in syngeneic mouse models of melanoma https://www.abstractsonline.com/pp8/#!/10517/presentation/16291

· 6022 - Synergistic anti-cancer effects of selinexor and bevacizumab in mouse xenograft models of glioblastoma https://www.abstractsonline.com/pp8/#!/10517/presentation/17979

· 6023 - Selinexor synergizes with temozolomide in preclinical models of glioblastoma independent of MGMT promoter methylation https://www.abstractsonline.com/pp8/#!/10517/presentation/17980

· 6025 - Baseline cytokine profiling in naïve and tumor-bearing Balb/c and C57BL/6 Charles River mice https://www.abstractsonline.com/pp8/#!/10517/presentation/17982

· 5832 - Utilizing small noncoding RNAs as biomarkers for selinexor treatment in gastric cancer https://www.abstractsonline.com/pp8/#!/10517/presentation/18815

· 4195 / 3 - Evaluation of the anti-myeloma effects of high and metronomic selinexor alone and in combination with duvelisib in vitro and in vivo https://www.abstractsonline.com/pp8/#!/10517/presentation/16809

· 5519 - Selinexor synergizes with anti-PD-1 antibody and inhibits tumor growth and metastasis in syngeneic mouse models of KRAS mutant colorectal cancer https://www.abstractsonline.com/pp8/#!/10517/presentation/17738

· 5536 - Selinexor inhibits lymphoma-leukemia tumor progression directly and through activation of anti-cancer immune response https://www.abstractsonline.com/pp8/#!/10517/presentation/17755

· 5314 - Selinexor, a selective inhibitor of nuclear export (SINE) compound, enhances the anti-tumor activity of Eribulin in leiomyosarcoma https://www.abstractsonline.com/pp8/#!/10517/presentation/18544

· 5330 - Nuclear protein export inhibitor selinexor chemotherapy combination for pancreatic cancer therapy https://www.abstractsonline.com/pp8/#!/10517/presentation/18560

20 presentations with Selinexor at AACR meeting in April / "99% inhibition of tumor growth with two mice cured sounds remarkable"

Top expert is a big fan of KPTI's science

Robert L. Coleman, M.D., FACOG, FACS



NEW SELINEXOR APPROVAL - Many more to come.



"I remember what Pfizer CEO said about buyouts. He wants to identify gems before they are fully developed, to maximise their investment return. Siendo is essentially that. Now is the time to buy for its potential in other solid tumors. Not later. Just a thought about the possibility of an imminent buyout."


Also see: Doctors With Questionable Affiliations: Vinay Prasad, Aaron Goodman, Al-Ola A Abdallah, Maha Hussain, Howard Scher


Older posts are regularly archived. To join my mailing list contact me.

Do your own research. This page does not provide investment advice.

DISCLAIMER: This is a private undertaking by Reza Ganjavi, MBA. This page is not sponsored by Karyopharm. This page is not an investment advice. Do your own research.

Site Under Reconstruction